In addition to its safety and tolerability, NB-002 activity was documented against numerous fungi involved in cutaneous infections, including Candida albicans, Microsporum canis, Epidermophyton floccosum, Trichophyton mentagrophytes and Trichophyton rubrum.
NanoBio is currently conducting a double-blind, placebo-controlled, phase 2 study to further investigate the efficacy and safety of NB-002 in 443 subjects with onychomycosis. All subjects have been enrolled, and the study is expected to be completed in February 2009.
The company's topical treatments are based on a novel anti-infective
platform comprising an oil-in-water emulsion and a surfactant. The
nanodroplets readily penetrate hair follicles and skin pores to reach the
site of infection without disrupting skin or mucous membranes. Upon contact
with the pathogen, the nanodroplets directly interact with the pathogen's
outer membranes to lyse the virus, fungus or bacteria.
Poster Titles -- Link to posters at http://www.nanobio.com
-- Safety, Tolerance, Pharmacokinetics, and Efficacy of Topical
Nanoemulsion NB-001 for the Treatment of Herpes Labialis
-- Development of a Novel Antiviral Drug (NB-001) for Topical Application
-- Safety, Tolerance, and Pharmacokinetics of Topical Nanoemulsion (NB-
002) for the Treatment of Onychomycosis
-- Development of a Novel Antifungal Drug (NB-002) for Topical Application
NanoBio(R) Corporation is a privately held biopharmaceutical company
focused on develo
|SOURCE NanoBio Corporation|
Copyright©2008 PR Newswire.
All rights reserved